<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Although the risk of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) has been well-described following autologous bone marrow transplantation (ABMT), the risk of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> has been poorly characterized </plain></SENT>
<SENT sid="1" pm="."><plain>We report the incidence and outcome of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> at 10-year follow-up in a large cohort of uniformly treated patients who underwent ABMT for non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: Between 1982 and 1997, 605 patients underwent ABMT for B-cell NHL, with uniform conditioning with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and total-body irradiation followed by reinfusion of autologous bone marrow purged with anti-B-cell monoclonal antibodies </plain></SENT>
<SENT sid="3" pm="."><plain>Current information on relapse of disease and <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> was obtained via an institutional review board-approved questionnaire sent to the referring oncologists </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Forty-two <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, six non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, 39 nonmelanoma <z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">skin cancers</z:e>, and 68 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) were observed at a median follow-up of 9.5 years </plain></SENT>
<SENT sid="5" pm="."><plain>A cumulative incidence model using <z:hpo ids='HP_0011420'>death</z:hpo> as a competing risk found that the 10-year incidence of <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancy</z:e> is 21%, with 10.0% non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The projected incidence of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> at 15 years is 29% </plain></SENT>
<SENT sid="7" pm="."><plain>The principal risk factor for <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancy</z:e> is increased age at ABMT (P = .0002) </plain></SENT>
<SENT sid="8" pm="."><plain>In the entire cohort, 9.6% of patients have died of <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancy</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Lengthy follow-up demonstrates a significant incidence of <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> after ABMT for NHL </plain></SENT>
<SENT sid="10" pm="."><plain>Although the incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> starts to plateau, the incidence of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> continues to rise </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">Second malignancies</z:e> are responsible for a significant fraction of overall mortality following ABMT </plain></SENT>
</text></document>